Key facts
- GRIN Therapeutics’s last known valuation is $445.0M (May 2025).
- It has raised $275.0M; the latest was Later Stage VC ($140.0M) in May 2025.
- Notable investors include Blackstone, Angelini Pharma.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for GRIN Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for GRIN Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GRIN Therapeutics
Operator of a biopharmaceutical company intended to develop precision therapies for pediatric neurodevelopmental disorders caused by mutations in the GRIN genes. The company specializes in assessing the safety and efficacy of the investigational therapy radiprodil for the treatment of serious neurodevelopmental disorders, including Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate (GRIN) related disorders, tuberous sclerosis complex (TSC), and focal cortical dysplasia (FCD), enabling patients suffering from neurodevelopmental disorders with treatment for neurological conditions.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 4
- Website
- grintherapeutics.com/
- Ownership
- Privately Held (backing)
GRIN Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GRIN Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GRIN Therapeutics in its N-PORT filings yet. We sweep new filings monthly.